Navigation Links
NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction
Date:7/14/2011

ves NeoStem not only access to a world class contract manufacturing cell therapy company but provides a platform and expertise around the evaluation, development and regulatory requirements to develop autologous, allogeneic, immunomodulatory and vaccine-based therapeutics. NeoStem also holds the worldwide exclusive license to VSEL(TM) Technology, which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem owns 80% of Athelos Corporation, a company developing a T-cell therapeutic with potential in a range of auto-immune conditions such as graft versus host disease, asthma and diabetes. Furthermore, NeoStem is building its Chinese presence by establishing an operations lab for cell-based manufacturing in Beijing as well as commercializing cellular therapies in China through the establishment of a network of hospitals.  NeoStem also owns a majority-interest in Suzhou Erye Pharmaceutical Company Limited, a world class manufacturing and distribution operation of generic antibiotics in China.

For more information, please visit: www.neostem.com.

About AmorcyteAmorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product, AMR–001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI ever conducted that has prospectively established a significant relationship between dose and effect. Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and other services for the cell therapy industry and a fully
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
2. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
3. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
4. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
5. NeoStem Announces Warrant Exercise by Principal Shareholder
6. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
7. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
8. NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
9. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
10. NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement
11. NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
(Date:7/10/2014)... , July 11, 2014  Major advances ... of cancer are being highlighted in a three-day ... from 10-12 July, 2014.  Renowned national and ... share best practices and exchange knowledge on modern ... accurate and efficient. The Summit ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Imaging has achieved proof-of-concept with the first fully automated ... CT angiography (cCTA) study. This technology, the first to ... the potential to eliminate the need for a separate ... decrease patient radiation exposure. This work in progress is ...
... Eli Lilly and Company (NYSE: LLY ) ... today the completion of Lilly,s $2 million upgrade to the ... at Argonne,s campus outside of Chicago. The APS is a ... Facility operated by Argonne. The Lilly Research Laboratories ...
Cached Medicine Technology:Rcadia's Fully Automatic Calcium Score Assessment from Coronary CTA Shows Potential to Eliminate Need for Separate Scan 2Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lilly's Beamline Capabilities 2Lilly and Argonne National Laboratory Announce $2 Million Upgrade to Lilly's Beamline Capabilities 3
(Date:7/12/2014)... News) -- If you make exercise fun, you,ll eat less ... 56 adults were led on a 1.4-mile walk and were ... scenic walk. The participants were given lunch after the walk, ... ate 35 percent more chocolate pudding for dessert than those ... another experiment, 46 adults were given mid-afternoon snacks after their ...
(Date:7/12/2014)... Using and carrying around a catheter bag can ... Va., decided that there needed to be an inconspicuous ... of our design," he said. , They then created ... an inconspicuous way to use and carry a catheter’s ... comfort and peace of mind. Producible in design variations, ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 “Critical ... - New and Late-Stage Four-Factor PCCs and Recombinant ... of the critical care market in the US, ... The report provides an estimation of market size ... It covers critical care indications that are being ...
(Date:7/12/2014)... A recent article released by Seattle's well known ... for those seeking cosmetic surgical procedures in summer months ... the heat begins to enliven the rainy Pacific Northwest, many ... that they didn’t work out as much during the winter ... sudden surge of people eager to look their best for ...
(Date:7/12/2014)... July 12, 2014 Maxim Peptide, a ... that are used solely in scientific experiments, is currently ... years in business, Maxim Peptide, which was created by ... a new and updated website that now features a ... has been updated with fascinating articles about peptide research, ...
Breaking Medicine News(10 mins):Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2
... ... WAYNE, Pa., Nov. 13 Escalon Medical Corp.,(Nasdaq: ESMC ... 2008., For the first quarter of fiscal 2009, the Company ... This,included product revenue of $8,669,000 for the first quarter of fiscal,2009, ...
... Nov. 13 The fourth annual EagleBank,Foundation Fight ... local hospitals were the primary beneficiaries: Shady Grove,Adventist ... and The,George Washington University Hospital, Providence Hospital and ... the Primary Care,Coalition of Montgomery County. The tournament ...
... FORT LAUDERDALE, Fla., Nov. 13 eDiets.com,Inc. (Nasdaq: ... fitness,and healthy lifestyle solutions, today announced results for the ... Revenues for the third quarter of 2008 were $4.8 ... Net loss for the quarter was $(3.2),million, or $(0.13) ...
... urging safe sex practices, study says , , THURSDAY, ... for pelvic inflammatory disease (PID) become highly vulnerable ... or months after treatment, researchers at Johns Hopkins ... the researchers, suggest that treating PID "with a ...
... Nov. 13 Watson,Pharmaceuticals, Inc. (NYSE: ... announced that its New Drug Application (NDA) ... a luteinizing hormone,releasing hormone (LHRH) agonist, has ... and Drug Administration (FDA). Watson is seeking ...
... 13 In a regular session of,the New York ... the cover of,a contentious election year and an economic ... Appeals (NYCOA) declined to hear the appeal of,Kathryn Jordan ... by a woman with Multiple Sclerosis. The appeal was,filed ...
Cached Medicine News:Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 7Health News:Escalon(R) Reports First Quarter Fiscal 2009 Results 8Health News:Fourth Annual EagleBank Foundation Fight Breast Cancer Golf Classic Raises Over $100,000 2Health News:eDiets.com(R) Announces Q3 2008 Results 2Health News:eDiets.com(R) Announces Q3 2008 Results 3Health News:eDiets.com(R) Announces Q3 2008 Results 4Health News:eDiets.com(R) Announces Q3 2008 Results 5Health News:eDiets.com(R) Announces Q3 2008 Results 6Health News:eDiets.com(R) Announces Q3 2008 Results 7Health News:Pelvic Inflammation Puts Girls at Risk for Repeat STIs 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 2Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 3Health News:Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 2Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 3Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 4Health News:Top NY Court Blinks in 'First Department' WPP Discrimination Power Play 5
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: